Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism

Fertility and Sterility

Volumn 77, Issue 2, 2002, Pages 270-273

  Bouloux, Pierre ^a   Warne, David W ^b   Loumaye, Ernest ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Serono International SA   (Switzerland)

^c Serono Inc   (United States)

Author keywords

hCG; Hypogonadotropic hypogonadism; Male; Recombinant human follicle stimulating hormone; Spermatogenesis; Testis

Indexed keywords

CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADOLESCENT; ADULT; ARTICLE; AZOOSPERMIA; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTORCHISM; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SPERMATOGENESIS; SPERMATOZOON COUNT; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY;

EID: 0036153562     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)02973-9     Document Type: Article

References (4)

1. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism
2. Recombinant follicle stimulating hormone; development of the first biotechnology product for the treatment of infertility
3. A low sperm concentration does not preclude fertility in men with isolated hypogonadotropic hypogonadism after gonadotropin therapy
4. Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism